T-ALL also frequently express a constitutive activation of the IL7-JAK-STAT5 pathway, through activating mutations in the genes for IL7 receptor (40), JAK3 (41) or STAT5 (42). The gene discussed is JAK3; the disease is acute lymphoblastic leukemia.